Cagrilintide vs Tirzepatide: A Research Comparison
Cagrilintide and Tirzepatide are both studied in metabolic research but act on different receptor families. Cagrilintide is a long-acting amylin analog studied within amylin and calcitonin-receptor signaling; Tirzepatide is a dual GIP/GLP-1 incretin-receptor agonist and an approved drug. Because amylin and incretin pathways are complementary, the two are sometimes studied together, including in combination research. The canonical difference is amylin versus incretin receptors. Both are supplied for research use only.
The core difference: amylin vs incretin receptors
The two compounds target different receptor systems that both influence appetite and energy balance. Cagrilintide is studied as an amylin analog acting on the amylin receptors (a calcitonin-receptor core paired with receptor-activity-modifying proteins) and the calcitonin receptor, pathways associated in research with satiety signaling. Tirzepatide is studied as a dual agonist of the GIP and GLP-1 incretin receptors, which amplify glucose-dependent insulin secretion. Amylin signaling versus incretin signaling is the defining distinction.
Structure and molecular profile
Cagrilintide (molecular weight near 4409.0 g/mol) is an acylated, disulfide-bridged amylin analog engineered for a long half-life. Tirzepatide (molecular weight near 4813.5 g/mol) is a 39-residue acylated peptide with aminoisobutyric acid substitutions. Confirm exact sequences and salt forms against each Certificate of Analysis.
Clinical and regulatory context
Tirzepatide is approved by the FDA and marketed as Mounjaro and Zepbound and has been studied extensively in human clinical trials, including the SURPASS and SURMOUNT programs. Cagrilintide is an investigational long-acting amylin analog that has been studied in human clinical trials, including in combination with the GLP-1 agonist semaglutide (studied as CagriSema), and has not received regulatory approval. These describe regulated or investigational drug programs; the Cagrilintide and Tirzepatide supplied here are research-use-only materials and are not those products.
How each is studied
Research with Cagrilintide examines amylin and calcitonin-receptor signaling and satiety and energy-homeostasis endpoints. Research with Tirzepatide examines incretin signaling, insulin secretion, and energy metabolism. Because amylin and incretin pathways are complementary, the two are sometimes combined in metabolic-research designs; used alone, Cagrilintide answers amylin-axis questions and Tirzepatide answers incretin-axis questions.
All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.